 |
Myriad Genetics Launches New Molecular Diagnostic Test
Jul 26, 2007
|
8.5 KB |
|
| |
Salt Lake City, UT, Jul 26, 2007—Myriad Genetics, Inc.
(NASDAQ: MYGN)
(www.myriad.com) announced
today that it has introduced a new product, TheraGuide 5-FU™, to
help predict which cancer patients are likely to suffer serious toxic
reactions to the drug...
|
|
Myriad Genetics Collaborates With AstraZeneca on Phase 2 Trials
Jun 19, 2007
|
8.8 KB |
|
| |
Salt Lake City, UT, June 19, 2007—Myriad Genetics, Inc.
(NASDAQ: MYGN) (www.myriad.com) today
announced the start of two Phase II trials for a new compound being
tested to treat patients with BRCA1 & BRCA2 positive breast and
ovarian cancer. AstraZeneca's ...
|
|
Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimer's Conference
Jun 11, 2007
|
9.0 KB |
|
| |
Salt Lake City, UT, Jun 11, 2007—Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) announced
today that it presented a mathematical comparison of a "Staggered
Start" and a "Randomized Withdrawal" clinical trial design with a
"Natural History Staggered Start" ...
|
|
$4 Trillion in Cost Savings to U.S. From New Disease-Modifying Alzheimer's Treatments
May 15, 2007
|
6.7 KB |
|
| |
Salt Lake City, UT, May 15, 2007—Myriad Genetics, Inc. (NASDAQ:
MYGN) reported today that a new study
has estimated the potential savings to the United States healthcare
system, from a disease-modifying Alzheimer's drug, at up to $4.0
trillion. These savings would be for new cases arising between ...
|
|
Myriad Genetics Reports Results for Third Quarter of Fiscal 2007
May 1, 2007
|
11.3 KB |
|
| |
Salt Lake City, UT, May 01, 2007—Myriad Genetics, Inc.
(NASDAQ:MYGN)
(www.myriad.com) today reported
consolidated financial results for the third quarter of fiscal 2007
and the nine months ended March 31, 2007.
Molecular diagnostic revenues for the thi...
|
|
Myriad Genetics Announces Third Quarter Fiscal 2007 Financial Results Conference Call
Apr 24, 2007
|
4.5 KB |
|
| |
Salt Lake City, UT, April 24, 2007—Myriad Genetics, Inc.
(NASDAQ:MYGN)
has arranged a conference call with the management
team to provide a company update. Peter D. Meldrum, President and
Chief Executive Officer will host the call along with Jay M. Moyes,
Chief Financial Officer, Gregory C. Crit...
|
|
Myriad Genetics Presents Tumor Origin Technology at AACR
Apr 18, 2007
|
6.6 KB |
|
| |
Salt Lake City, UT, April 18, 2007—Myriad Genetics, Inc.
(NASDAQ: MYGN)
(www.myriad.com) announced
today that it presented studies for a new technology that might be
used to determine the original location of a metastatic tumor, on
Monday, April 16, 2007 at t...
|
|
Myriad Genetics Presents Azixa's Mode of Action at AACR
Apr 17, 2007
|
6.6 KB |
|
| |
Salt Lake City, UT, April 17, 2007—Myriad Genetics, Inc.
(NASDAQ: MYGN)
(www.myriad.com) announced
today that it presented studies that characterize the mode of action
of its investigational new drug, Azixa™, as a vascular disrupting
agent, at the annua...
|
|
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa in Metastatic Brain Cancer
Mar 27, 2007
|
8.0 KB |
|
| |
SALT LAKE CITY, UT, March 27, 2007—Myriad Genetics, Inc. (NASDAQ: MYGN)
(www.myriad.com) announced
today that it has initiated a Phase 2 human clinical trial of its
therapeutic candidate, Azixa™ (MPC-6827), in patients with
melanoma that has spread to the...
|
|
Myriad Genetics Completes Enrollment in Second Phase 3 Clinical Trial of Flurizan™ in Alzheimer's Disease
Mar 20, 2007
|
9.3 KB |
|
| |
SALT LAKE CITY, UT, March 20, 2007—Myriad Genetics, Inc.
(NASDAQ: MYGN)
(www.myriad.com) announced today
that it has completed enrollment of patients in its global Phase 3
clinical trial of Flurizan™ (tarenflurbil) in Alzheimer's disease.
The glo...
|
|
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa™ in Brain Cancer
Mar 8, 2007
|
8.1 KB |
|
| |
SALT LAKE CITY, UT, Mar 08, 2007—Myriad Genetics, Inc.
(NASDAQ: MYGN) (www.myriad.com) announced
today that it has initiated the first Phase 2 human clinical trial of
its therapeutic candidate, Azixa™ (MPC-6827), in patients with
brain cancer.
The...
|
|
Myriad Presents Additional Flurizan™ Phase 2 Study Data Demonstrating Benefit in Alzheimer's Patients
Mar 5, 2007
|
9.6 KB |
|
| |
SALT LAKE CITY, UT, March 05, 2007—Myriad Genetics, Inc.
(NASDAQ: MYGN) (www.myriad.com) announced
today that it presented additional results of its completed Phase 2
follow-on study of Flurizan™ in patients with mild Alzheimer's
disease at the annual mee...
|
|
Myriad Genetics Announces Sale of Common Stock
Feb 8, 2007
|
5.5 KB |
|
| |
SALT LAKE CITY, UT, February 08, 2007—Myriad Genetics, Inc.
(NASDAQ: MYGN) announced today that it sold
3,000,000 shares of its common stock pursuant to an effective shelf
registration statement. Myriad has also granted the underwriter a
30-day option to purchase an additional 450,000 shares of co...
|
|
Myriad Genetics Commences Public Offering of Common Stock
Feb 7, 2007
|
5.4 KB |
|
| |
SALT LAKE CITY, UT, February 07, 2007—Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that it is
selling 3,000,000 shares of its common stock pursuant to an effective
shelf registration statement. Myriad will also grant the underwriter
a 30-day option to purchase an additional 450,000 shares of...
|
|
Myriad Genetics Reports Results for Second Quarter of Fiscal 2007
Feb 6, 2007
|
12.3 KB |
|
| |
SALT LAKE CITY, February 06, 2007—Myriad Genetics, Inc. (NASDAQ: MYGN) today reported financial
results for the second quarter of fiscal 2007 and the six months
ended December 31, 2006.
For the second fiscal quarter of 2007, molecular diagnostics revenues
increased by 46% to $34.2 million, f...
|
|
Myriad Genetics Announces Second Quarter Fiscal 2007 Financial Results Conference Call
Jan 23, 2007
|
4.2 KB |
|
| |
SALT LAKE CITY--(BUSINESS WIRE)--Jan. 23, 2007--Myriad Genetics,
Inc. (NASDAQ:MYGN) has arranged a conference call with the management
team to provide a company update. Peter Meldrum, President and Chief
Executive Officer will host the call along with Jay Moyes, Chief
Financial Officer, Gregory Critchfield, M.D., President of Myriad
Genetic La...
|
|
Myriad Genetics Announces Results of Phase 2 Prostate Cancer Trial
Jan 8, 2007
|
6.6 KB |
|
| |
SALT LAKE CITY, January 8, 2007—Myriad Genetics, Inc.
(NASDAQ: MYGN)
announced today the results of
its multi-center, double-blind, placebo-controlled human clinical
trial of MPC-7869 (R-flurbiprofen) in prostate cancer. The clinical
trial was designed to evaluate the safety of MPC-7869 and to c...
|
|
Myriad Genetics to Present at the JPMorgan Healthcare Conference on January 8, 2007
Jan 2, 2007
|
5.8 KB |
|
| |
SALT LAKE CITY, January 2, 2007—Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that its
President and CEO, Peter Meldrum, is scheduled to present an overview
of the Company at the 25th Annual JPMorgan Healthcare Conference, at
8:00 am Pacific Time on January 8, 2007, at the Westin St. Francis
...
|
|
Myriad Genetics, Inc. Reports Results for First Quarter of Fiscal 2007
Nov 7, 2006
|
14.0 KB |
|
| |
Salt Lake City, November 7, 2006—Myriad Genetics, Inc.
(Nasdaq: MYGN) (www.myriad.com)
today reported financial results for the first quarter of
fiscal 2007. For the three-month period ended September 30, 2006, molecular
diagnostic revenue increased to $30.9 ...
|
|
Myriad Genetics Sponsors Clinical Trial in Pancreatic Cancer
Oct 24, 2006
|
8.1 KB |
|
| |
Salt Lake City, October, 24, 2006—Myriad Genetics, Inc.
(Nasdaq: MYGN) (www.myriad.c
om), announced today that the Company is providing the genetic
testing component of a new clinical trial in patients with pancreatic cancer
being run by researchers at Johns Hop...
|
|
|
